tiprankstipranks
Trending News
More News >
Bal Pharma Limited (IN:BALPHARMA)
:BALPHARMA
India Market
Advertisement

Bal Pharma Limited (BALPHARMA) AI Stock Analysis

Compare
0 Followers

Top Page

IN:BALPHARMA

Bal Pharma Limited

(BALPHARMA)

Rating:55Neutral
Price Target:
₹100.00
▲(12.07% Upside)
The overall stock score reflects moderate financial performance with stable gross margins, but significant challenges in profitability and leverage. Technical indicators suggest a bearish market trend, and the valuation is moderate, offering limited attractiveness to both growth and income investors.

Bal Pharma Limited (BALPHARMA) vs. iShares MSCI India ETF (INDA)

Bal Pharma Limited Business Overview & Revenue Model

Company DescriptionBal Pharma Limited is an Indian pharmaceutical company that engages in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company operates in various therapeutic segments such as diabetology, cardiology, dermatology, gastroenterology, and more. Bal Pharma is known for its wide range of generic and specialty products, which are distributed domestically and internationally.
How the Company Makes MoneyBal Pharma Limited generates revenue primarily through the sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's revenue streams include domestic sales of branded and generic formulations, as well as export sales to international markets. Bal Pharma's product portfolio spans across various therapeutic categories, allowing it to address diverse healthcare needs. Additionally, the company may engage in strategic partnerships and collaborations to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Bal Pharma Limited Financial Statement Overview

Summary
Bal Pharma Limited demonstrates moderate growth with stable gross margins. However, it faces profitability challenges and high leverage, which could pose risks in downturns. Cash flow inconsistency further impacts financial stability, requiring improved cash management strategies.
Income Statement
65
Positive
Bal Pharma Limited shows moderate revenue growth over the years, with an increase from 2020 to 2024. The gross profit margin has been relatively stable, indicating decent cost management. However, the net profit margin is low, which suggests challenges in converting revenue into net income. The EBIT and EBITDA margins have seen fluctuations, reflecting operational efficiency issues.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio is high, indicating significant leverage which could pose risk if not managed well. ROE has improved annually, showing better returns on shareholder equity. The equity ratio is relatively low, suggesting a higher reliance on debt to finance assets.
Cash Flow
55
Neutral
Operating cash flow has been inconsistent, with a significant drop in 2025 compared to previous years. Free cash flow has also faced volatility, turning negative in some years. The ratios of cash flows to net income indicate challenges in cash generation relative to earnings, potentially impacting liquidity.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.24B3.03B3.39B3.04B2.81B2.51B
Gross Profit1.13B730.18M770.20M1.31B1.11B993.03M
EBITDA347.10M317.63M320.23M245.00M287.64M257.82M
Net Income76.63M72.15M73.92M25.72M56.12M47.42M
Balance Sheet
Total Assets3.40B3.36B3.20B3.13B2.61B2.40B
Cash, Cash Equivalents and Short-Term Investments261.56M105.19M199.29M90.81M60.84M39.71M
Total Debt1.55B1.50B1.42B1.31B1.07B1.12B
Total Liabilities2.71B2.58B2.50B2.49B2.02B1.87B
Stockholders Equity687.92M774.16M692.94M637.89M586.27M535.81M
Cash Flow
Free Cash Flow59.25M-145.55M118.26M-164.89M192.39M183.68M
Operating Cash Flow59.25M42.32M228.06M-18.43M277.08M217.81M
Investing Cash Flow0.00-156.53M-188.91M-221.82M-94.85M-49.80M
Financing Cash Flow0.0090.12M-12.06M244.00M-181.34M-166.32M

Bal Pharma Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price89.23
Price Trends
50DMA
96.20
Negative
100DMA
98.80
Negative
200DMA
104.04
Negative
Market Momentum
MACD
-2.49
Negative
RSI
46.21
Neutral
STOCH
46.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALPHARMA, the sentiment is Negative. The current price of 89.23 is below the 20-day moving average (MA) of 90.76, below the 50-day MA of 96.20, and below the 200-day MA of 104.04, indicating a bearish trend. The MACD of -2.49 indicates Negative momentum. The RSI at 46.21 is Neutral, neither overbought nor oversold. The STOCH value of 46.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BALPHARMA.

Bal Pharma Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
₹2.48B30.08
2.36%2924.94%
60
Neutral
₹1.78B49.80
-4.74%-41.53%
58
Neutral
₹1.21B19.78
-16.39%-409.96%
55
Neutral
₹1.41B20.16
1.32%-14.16%-6.46%
54
Neutral
₹1.31B309.48
15.13%-4518.87%
51
Neutral
$7.89B-0.33-41.61%2.23%23.26%-2.03%
39
Underperform
₹1.52B
-31.91%-38.46%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:BALPHARMA
Bal Pharma Limited
90.39
-47.08
-34.25%
IN:AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd.
66.08
-7.37
-10.03%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
103.75
24.20
30.42%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
74.02
-11.19
-13.13%
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
75.86
-54.94
-42.00%
IN:VAISHALI
Vaishali Pharma Ltd.
12.16
-6.63
-35.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025